---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011297"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:53:28.687188+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences Q2 net loss $10.1M; PRECISE-AD enrollment >50%, no ARIA; raised $21.6M in July

## Summary
- Net loss $10.1M for Q2 2025 vs $2.6M a year ago; R&D spend $8.7M on PRECISE-AD trial.
- Cash $4.5M at June 30; raised $21.6M gross proceeds in July via offerings and warrant exercises.
- PRECISE-AD Phase 1b: over 50% of 128 patients enrolled; no ARIA or dropouts to date.
- FDA granted Fast Track Designation for PMN310 in Alzheimer's disease in July 2025.
- Company expects blinded interim results in 2Q 2026, final topline in 4Q 2026.

## SEC filing metadata
- accession: 0001558370-25-011297
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/0001558370-25-011297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011297
- JSON: https://secwatch.observer/filing/0001558370-25-011297.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.